Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.45 |
| ▸ | RXRB | P28702 | 4/20 | 0.45 |
| ▸ | RXRG | P48443 | 4/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | PAK4 | O96013 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491751 | 0.84 | JUN (0.37) | RXRARXRBRXRGHTR2AHTR2C | |
| SCHEMBL19300445 | 0.83 | ROCK1 (0.50) | RXRARXRBRXRGROCK1JAK2 | |
| SCHEMBL6478895 | 0.79 | PDGFRB (0.57) | RXRARXRBRXRGROCK1JAK2 | |
| SCHEMBL7246192 | 0.77 | SCN9A (0.47) | ROCK1JAK2JAK3PTK2AURKA | |
| SCHEMBL7246188 | 0.72 | SCN9A (0.58) | — | |
| SCHEMBL30421438 | 0.71 | ROCK1 (0.49) | RXRARXRBRXRGHTR2AHTR2C | |
| SCHEMBL6482037 | 0.71 | EGFR (0.54) | JAK3BTK | |
| SCHEMBL17486069 | 0.68 | JAK2 (0.53) | RXRARXRBRXRGROCK1JAK2 | |
| SCHEMBL5063173 | 0.68 | JAK2 (0.53) | RXRARXRBRXRGROCK1JAK2 | |
| SCHEMBL24359312 | 0.66 | NOTUM (0.50) | HTR2AHTR2CHTR2BNOTUMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | disclosed |
| EP-1390354-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | Amgen Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2002083653-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | PKD1, PKD2, GLS | RXRA 3161/4885RXRB 3119/4885RXRG 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.